Medivizor

Title of notification

Here comes the notification
X
 
icon
breast cancer | Research | 10 pages | source: The Lancet. Oncology | Added Nov 07, 2021

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.

icon
breast cancer | Research | 10 pages | source: International journal of radiation oncology, biology, physics | Added Oct 31, 2021

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: The Journal of Rheumatology | Added Oct 25, 2021

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a conventional synthetic disease-modifying antirheumatic drug (csDMARD) and placebo or methotrexate (MTX; Otrexup) alone.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Oct 16, 2021

Treatment responses to tofacitinib with additional therapies in patients with rheumatoid arthritis.

This study assessed the responses of patients with rheumatoid arthritis (RA) to tofacitinib (Xeljanz), tofacitinib with methotrexate (MTX; Otrexup), and adalimumab (Humira) with MTX. The data showed that some patients did not require combined therapy to achieve higher responses, however, overall, greater responses were achieved with tofacitinib and MTX compared to tofacitinib alone.

icon
rheumatoid arthritis | Research | 10 pages | source: Scientific reports | Added Oct 11, 2021

Do biologics increase the risk of blood clots in patients with rheumatoid arthritis?

This study looked at the risk of blood clots in patients with rheumatoid arthritis (RA) treated with biologics. It found that there was no significant increase in the risk of blood clots with biologics compared to other RA treatments.

icon
icon
breast cancer | Research | Treatment | 10 pages | source: Targeted oncology | Added Oct 09, 2021

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).  

icon
rheumatoid arthritis | Research | 10 pages | source: Annals of the rheumatic diseases | Added Oct 09, 2021

Is there a relationship between fatigue and disease activity in patients with early rheumatoid arthritis?

This study investigated the occurrence of fatigue (tiredness) in patients with early rheumatoid arthritis (RA) and identified predictors of fatigue after 24 months. The data showed that patients with early disease remission had a rapid, sustained reduction in fatigue and that low disease activity at diagnosis predicted a higher risk of fatigue at 24 months.

icon
icon
rheumatoid arthritis | Research | Treatment | 10 pages | source: Arthritis Research & Therapy | Added Oct 05, 2021

Is peficitinib an effective treatment for rheumatoid arthritis?

This study looked at the use of peficitinib (Smyraf) for the treatment of rheumatoid arthritis (RA) from the perspective of patients and their doctors. It found that peficitinib improved symptoms of RA and led to increased ability to work and carry out daily activities compared to placebo.

icon
icon
breast cancer | Research | Lifestyle | 10 pages | source: Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer | Added Oct 05, 2021

Evaluating the association of physical activity and sedentary behavior with fatigue, pain, and depressive symptoms among breast cancer survivors.

This study examined the association of physical activity (PA) and sedentary time (ST) with pain, fatigue, and depressive symptoms over time among survivors of breast cancer (BC). The data showed that lower ST and higher PA is associated with lower depressive symptoms in long-term survivors of BC.

icon
icon
breast cancer | Research | Treatment | 10 pages | source: Cancer Medicine | Added Oct 03, 2021

Evaluating the occurrence and predictors of peripheral nerve disease after breast cancer treatment.

This study evaluated the occurrence and clinical predictors of peripheral neuropathy (PN; nerve damage) in long-term survivors of breast cancer (BC). The data showed that PN is an important long-term consequence of taxane-based chemotherapy in survivors of BC.

View

Conditions

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?